HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Open accessThe DOI matches its Crossref record; 53 of the 56 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a major component of the immune-suppressive network described in cancer and many other pathological conditions. We demonstrate that although MDSCs from peripheral lymphoid organs and the tumor site share similar phenotype and morphology, these cells display profound functional differences. MDSC from peripheral lymphoid organs suppressed antigen-specific CD8+ T cells but failed to inhibit nonspecific T cell function. In sharp contrast, tumor MDSC suppressed both antigen-specific and nonspecific T cell activity. The tumor microenvironment caused rapid and dramatic up-regulation of arginase I and inducible nitric oxide synthase in MDSC, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphate–oxidase and reactive oxygen species in these cells. In contrast to MDSC from the spleen, MDSC from the tumor site rapidly differentiated into macrophages. Exposure of spleen MDSC to hypoxia resulted in the conversion of these cells to nonspecific suppressors and their preferential differentiation to macrophages. Hypoxia-inducible factor (HIF) 1α was found to be primarily responsible for the observed effects of the tumor microenvironment on MDSC differentiation and function. Thus, hypoxia via HIF-1α dramatically alters the function of MDSC in the tumor microenvironment and redirects their differentiation toward tumor-associated macrophages, hence providing a mechanistic link between different myeloid suppressive cells in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia can abolish the cell killing activity of NK cells, which correlates with an increase in HIF-1α [78].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“tumor hypoxia generates macrophages that can suppress T cell responses. This suppressive phenotype is mediated by hypoxic induction of arginase 1 and nitric oxide synthase, both that restrict T cell activation. Strikingly, induction of this hypoxic pathway in macrophages is required for optimal tumor growth [84, 85].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the mesothelioma microenvironment, the availability of glucose is critical, and competition for this molecule impacts on T-cell function and the recruitment of immune infiltrating cells, promoting angiogenesis [119,120,121,122].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, tumor hypoxia and/or HIFs can attract myeloid-derived suppressor cells (Corzo et al., 2010), regulatory T-cells (Clambey et al., 2012), and tumor-associated macrophages (Doedens et al., 2010;Imtiyaz et al., 2010) with immunosuppressive functions.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Corzo et al., 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which suggests that 32-134D inhibited the expression of these latter mRNAs in immune or other stromal cell types, where HIFs are known to play critical roles (56–61), rather than in tumor cells.”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [56]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 2×
“Extensive studies in recent years suggested several mechanisms of MDSC-mediated immune suppression that involve arginine (Bronte and Zanovello, 2005; Rodríguez and Ochoa, 2008) and cysteine (Srivastava et al., 2010) metabolism, expression of some surface molecules (Pan et al., 2010), up-regulation…”
BackgroundMyeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Self-citationSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationAlmand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Self-citationMovahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Cited by
Items 201–300 of 1,000
Yin, Y., Huang, X., Lynn, K. D., & Thorpe, P. E. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0073 · Cited by 149
Cysteine Cathepsins in Tumor-Associated Immune Cells
Jakoš, T., Pišlar, A. H., Jewett, A., & Kos, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02037 · Cited by 158
Roles of CCL2-CCR2 Axis in the Tumor Microenvironment
Kadomoto, S., Izumi, K., & Mizokami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168530 · Cited by 145
Baxevanis, C. N., Fortis, S. P., & Perez, S. A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.018 · Cited by 167
Hou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 145
Myeloid Cells in Glioblastoma Microenvironment
Leo, A. D., Ugolini, A., & Veglia, F. (2020) · Cells · doi:10.3390/cells10010018 · Cited by 168
Jordan, K. R., Amaria, R. N., Ramirez, O., Callihan, E. B., Gao, D., Borakove, M., Manthey, E., Borges, V. F., & McCarter, M. D. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1475-x · Cited by 144
Noman, M. Z., Janji, B., Hu, S., Wu, J. C., Martelli, F., Bronte, V., & Chouaib, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0405 · Cited by 143
PGE2-Driven Induction and Maintenance of Cancer-Associated Myeloid-Derived Suppressor Cells
Obermajer, N., Wong, J. L., Edwards, R. P., Odunsi, K., Moysich, K., & Kalinski, P. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.695417 · Cited by 144
Lu, T., & Gabrilovich, D. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2939 · Cited by 142
Self-citationVascular normalisation as the stepping stone into tumour microenvironment transformation
Magnussen, A. L., & Mills, I. G. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01330-z · Cited by 146
Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?
Huang, Y., Lin, D., & Taniguchi, C. M. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9178-y · Cited by 142
Höchst, B., Schildberg, F. A., Sauerborn, P., Gäbel, Y. A., Gevensleben, H., Goltz, D., Heukamp, L. C., Türler, A., Ballmaier, M., Gieseke, F., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.033 · Cited by 147
Sormendi, S., & Wielockx, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00040 · Cited by 141
Danilin, S., Merkel, A. R., Johnson, J. R., Johnson, R. W., Edwards, J. R., & Sterling, J. A. (2012) · OncoImmunology · doi:10.4161/onci.21990 · Cited by 140
Relief of tumor hypoxia unleashes the tumoricidal potential of neutrophils
Mahiddine, K., Blaisdell, A., Ma, S., Créquer-Grandhomme, A., Lowell, C. A., & Erlebacher, A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130952 · Cited by 139
Takeuchi, S., Baghdadi, M., Tsuchikawa, T., Wada, H., Nakamura, T., Abe, H., Nakanishi, S., Usui, Y., Higuchi, K., Takahashi, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2921 · Cited by 138
miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS
Wu, M.-Z., Cheng, W.-C., Chen, S.-F., Nieh, S., O’Connor, C., Liu, C.-L., Tsai, W.-W., Wu, C.-J., Martin, L., Lin, Y.-S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3615 · Cited by 138
Self-citationTargeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Joshi, S., & Sharabi, A. B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108114 · Cited by 154
How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions
Bruger, A. M., Dorhoi, A., Esendağlı, G., Barczyk‐Kahlert, K., van der Bruggen, P., Lipoldová, M., Perečko, T., Santibanez, J. F., Saraiva, M., Ginderachter, J. A. V., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2170-8 · Cited by 150
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 138
Yang, T., Yao, Q., Cao, F., Liu, Q., Liu, B., & Wang, X. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s109695 · Cited by 143
Bigos, K. J. A., Quiles, C. G., Lunj, S., Smith, D. J., Krause, M., Troost, E. G. C., West, C., Hoskin, P., & Choudhury, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1331355 · Cited by 166
In vivo suppressive function of myeloid‐derived suppressor cells is limited to the inflammatory site
Haverkamp, J. M., Crist, S. A., Elzey, B. D., Cimen, C., & Ratliff, T. L. (2011) · European Journal of Immunology · doi:10.1002/eji.201041069 · Cited by 133
Lin, Y., Yang, X., Liu, W., Li, B., Yin, W., Shi, Y., & He, R. (2017) · Oncogene · doi:10.1038/onc.2016.516 · Cited by 143
Innate immune mediators in cancer: between defense and resistance
Berraondo, P., Minute, L., Ajona, D., Corrales, L. P., Melero, I., & Pío, R. (2016) · Immunological Reviews · doi:10.1111/imr.12464 · Cited by 146
Myeloid-Derived Suppressor Cells and anti-tumor T cells: a complex relationship
Monu, N. R., & Frey, A. B. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.673191 · Cited by 144
Augustin, R. C., Delgoffe, G. M., & Najjar, Y. G. (2020) · Cancers · doi:10.3390/cancers12123802 · Cited by 129
Fu, Z., Mowday, A. M., Smaill, J. B., Hermans, I. F., & Patterson, A. V. (2021) · Cells · doi:10.3390/cells10051006 · Cited by 147
The roles of arginases and arginine in immunity
Canè, S., Geiger, R., & Bronte, V. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01098-2 · Cited by 164
Targeting myeloid cells in the tumor sustaining microenvironment
Schupp, J., Krebs, F. K., Zimmer, N., Trzeciak, E., Schuppan, D., & Tuettenberg, A. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.013 · Cited by 126
Sumida, K., Wakita, D., Narita, Y., Masuko, K., Terada, S., Watanabe, K., Satoh, T., Kitamura, H., & Nishimura, T. (2012) · European Journal of Immunology · doi:10.1002/eji.201142335 · Cited by 126
Zhao, Q., Chu, Z., Zhu, L., Yang, T., Wang, P., Liu, F., Huang, Y., Zhang, F., Zhang, X., Ding, W., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00637 · Cited by 126
Yu, M., Duan, X., Cai, Y., Zhang, F., Jiang, S., Han, S., Shen, J., & Shuai, X. (2019) · Advanced Science · doi:10.1002/advs.201900037 · Cited by 129
Hypoxia-inducible factors in cancer stem cells and inflammation
Peng, G., & Liu, Y. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.003 · Cited by 123
Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?
Kumar, V. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9349-9 · Cited by 145
Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy
Wegiel, B., Vuerich, M., Daneshmandi, S., & Seth, P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00284 · Cited by 133
Cancer Metabolism Drives a Stromal Regenerative Response
Schwörer, S., Vardhana, S. A., & Thompson, C. B. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.015 · Cited by 123
Siska, P. J., Singer, K., Evert, K., Renner, K., & Kreutz, M. (2020) · Immunological Reviews · doi:10.1111/imr.12846 · Cited by 123
Policastro, L. L., Ibañez, I. L., Notcovich, C., Duran, H. A., & Podhajcer, O. L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4367 · Cited by 120
Myeloid‐derived suppressor cells: the dark knight or the joker in viral infections?
Goh, C., Narayanan, S., & Hahn, Y. S. (2013) · Immunological Reviews · doi:10.1111/imr.12084 · Cited by 121
Ni, K., Lan, G., Song, Y., Hao, Z., & Lin, W. (2020) · Chemical Science · doi:10.1039/d0sc01949f · Cited by 121
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01795-9 · Cited by 120
Tumor-Associated Neutrophils and Macrophages—Heterogenous but Not Chaotic
Wu, L., & Zhang, X. H.-F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.553967 · Cited by 135
Alicea-Torres, K., Sanseviero, E., Gui, J., Chen, J., Veglia, F., Yu, Q., Donthireddy, L., Kossenkov, A., Lin, C., Fu, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22033-2 · Cited by 118
Self-citationZheng, H., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Liu, J., Fan, Q., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01356-7 · Cited by 135
Sezginer, O., & Ünver, N. (2024) · Inflammation Research · doi:10.1007/s00011-024-01907-3 · Cited by 140
Lee, S. H., Park, O. K., Kim, J., Shin, K., Pack, C., Kim, K., Ko, G., Lee, N., Kwon, S., & Hyeon, T. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b04621 · Cited by 127
The Generation and Identity of Human Myeloid-Derived Suppressor Cells
Bergenfelz, C., & Leandersson, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00109 · Cited by 125
Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea
Cubillos-Zapata, C., Avendaño-Ortiz, J., Hernandez-Jimenez, E., Toledano, V., Casas-Martin, J., Varela-Serrano, A., Torres, M., Almendros, I., Casitas, R., Fernández-Navarro, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00833-2017 · Cited by 116
Isaacs, J. T., Antony, L., Dalrymple, S. L., Brennen, W. N., Gerber, S., Hammers, H., Wissing, M., Kachhap, S., Luo, J., Xing, L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2730 · Cited by 116
Chesney, J. A., Mitchell, R. A., & Yaddanapudi, K. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-458rrr · Cited by 124
Falck‐Jones, S., Vangeti, S., Yu, M., Falck‐Jones, R., Cagigi, A., Badolati, I., Österberg, B., Lautenbach, M. J., Åhlberg, E., Lin, A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144734 · Cited by 126
Orchestration of Angiogenesis by Immune Cells
Bruno, A., Pagani, A., Pulze, L., Albini, A., Dallaglio, K., Noonan, D. M., & Mortara, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00131 · Cited by 126
Guillerey, C., Nakamura, K., Vučković, S., Hill, G. R., & Smyth, M. J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2135-z · Cited by 129
Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia
Phung, C. D., Tran, T. H., Pham, L. M., Nguyen, H. T., Jeong, J., Yong, C. S., & Kim, J. O. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.029 · Cited by 115
Miska, J. M., Rashidi, A., Lee-Chang, C., Gao, P., Lopez‐Rosas, A., Zhang, P., Burga, R. A., Castro, B. A., Xiao, T., Han, Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc8929 · Cited by 127
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
Gowd, V., Ahmad, A., Tarique, M., Suhail, M., Zughaibi, T. A., Tabrez, S., & Khan, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.026 · Cited by 112
The role of tumor-associated macrophages in tumor vascularization
Guo, C., Buranych, A., Sarkar, D., Fisher, P. B., & Wang, X.-Y. (2013) · Vascular Cell · doi:10.1186/2045-824x-5-20 · Cited by 114
Xiao, P., Wan, X., Cui, B., Liu, Y., Qiu, C., Rong, J., Zheng, M., Song, Y., Chen, L., He, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1063772 · Cited by 117
Brooks, J. M., de Menezes, A. N., Ibrahim, M., Archer, L., Lal, N., Bagnall, C. J., von Zeidler, S. V., Valentine, H. R., Spruce, R. J., Batis, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3314 · Cited by 125
Glucose metabolism of TAMs in tumor chemoresistance and metastasis
Liu, J., & Cao, X. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.03.008 · Cited by 129
Salman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156774 · Cited by 111
Immunologically augmented cancer treatment using modern radiotherapy
Durante, M., Reppingen, N., & Held, K. D. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.007 · Cited by 132
Huang, M., Wu, R., Chen, L., Peng, Q., Li, S., Zhang, Y., Zhou, L., & Duan, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02243 · Cited by 119
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Li, L., Zhang, F., Liu, Z., & Fan, Z. (2023) · Cancers · doi:10.3390/cancers15010321 · Cited by 135
Tumor metabolism as modulator of immune response and tumor progression
Gottfried, E., Kreutz, M. P., & Mackensen, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.009 · Cited by 125
Cimen Bozkus, C., Elzey, B. D., Crist, S. A., Ellies, L. G., & Ratliff, T. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500959 · Cited by 111
Albeituni, S., Ding, C., Liu, M., Hu, X., Luo, F., Kloecker, G. H., Bousamra, M., Zhang, H., & Yan, J. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501853 · Cited by 120
Lan, J., Li, R., Yin, L., Deng, L., Gui, J., Chen, B.-Q., Zhou, L., Meng, M., Huang, Q., Mo, X., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.01.071 · Cited by 119
The Emerging “Hallmarks” of Metabolic Reprogramming and Immune Evasion: Distinct or Linked?
Kareva, I., & Hahnfeldt, P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3696 · Cited by 124
Macrophage-tumor cell interactions regulate the function of nitric oxide
Rahat, M. A., & Hemmerlein, B. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00144 · Cited by 109
Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity
Terry, S., Buart, S., & Chouaïb, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01625 · Cited by 117
Myeloid-Derived Suppressor Cells in the Development of Lung Cancer
Ortiz, M. L., Lu, L., Ramachandran, I., & Gabrilovich, D. I. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0129 · Cited by 110
Self-citationYan, D., Yang, Q., Shi, M., Zhong, L., Wu, C., Meng, T., Yin, H., & Zhou, J. (2013) · European Journal of Immunology · doi:10.1002/eji.201343472 · Cited by 109
Myeloid-Derived Suppressor Cells in Colorectal Cancer
Siemińska, I., & Baran, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01526 · Cited by 125
Jantsch, J., Wiese, M., Schödel, J., Castiglione, K., Gläsner, J., Kolbe, S., Mole, D., Schleicher, U., Eckardt, K.-U., Hensel, M., et al. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1210683 · Cited by 108
Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells
Alissafi, T., Hatzioannou, A., Mintzas, K., Barouni, R. M., Banos, A., Sormendi, S., Polyzos, A., Xilouri, M., Wielockx, B., Gogas, H. J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120888 · Cited by 117
Increased immunosuppression impairs tissue homeostasis with aging and age-related diseases
Salminen, A. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01988-7 · Cited by 124
Targeting myeloid-derived suppressor cells for cancer immunotherapy
Liu, Y., Wei, G., Cheng, W. A., Dong, Z., Sun, H., Lee, V. Y., Cha, S.-C., Smith, D. L., Kwak, L. W., & Qin, H. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2175-3 · Cited by 102
MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation
Yaddanapudi, K., Rendon, B. E., Lamont, G. J., Kim, E. J., Rayyan, N. A., Richie, J., Albeituni, S., Waigel, S. J., Wise, A. D., & Mitchell, R. A. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0070-t · Cited by 115
Myeloid-derived suppressor cells and their role in pancreatic cancer
Pergamo, M., & Miller, G. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.65 · Cited by 115
Laoui, D., Overmeire, E. V., Movahedi, K., den Bossche, J. V., Schouppe, E., Mommer, C., Nikolaou, A., Morias, Y., BAETSELIER, P. D., & Ginderachter, J. A. V. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.06.007 · Cited by 112
Guipaud, O., Jaillet, C., Clément-Colmou, K., François, A., Supiot, S., & Milliat, F. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170762 · Cited by 121
Hypoxia in Solid Tumors: How Low Oxygenation Impacts the “Six Rs” of Radiotherapy
Rakotomalala, A., Escande, A., Furlan, A., Meignan, S., & Lartigau, E. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.742215 · Cited by 128
Chen, Q., Xu, L., Chen, J., Yang, Z., Liang, C., Yang, Y., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.021 · Cited by 104
Myeloid-Derived Suppressor Cells in Solid Tumors
Ma, T., Renz, B. W., Ilmer, M., Koch, D. T., Yang, Y., Werner, J., & Bazhin, A. V. (2022) · Cells · doi:10.3390/cells11020310 · Cited by 122
Turning Tumors into Vaccines: Co-opting the Innate Immune System
van den Boorn, J. G., & Hartmann, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.011 · Cited by 116
The network of immunosuppressive pathways in glioblastoma
Mangani, D., Weller, M., & Roth, P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.011 · Cited by 111
DAMP-TLR-cytokine axis dictates the fate of tumor
Patidar, A., Selvaraj, S., Sarode, A. Y., Chauhan, P. S., Chattopadhyay, D., & Saha, B. (2017) · Cytokine · doi:10.1016/j.cyto.2017.10.004 · Cited by 109
Cheng, Y., Tang, X.-Y., Li, Y.-X., Zhao, D.-D., Cao, Q.-H., Wu, H.-X., Yang, H.-B., Hao, K., & Yang, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2912 · Cited by 102
Lactate: The Mediator of Metabolism and Immunosuppression
Zhang, Y., Zhai, Z., Duan, J., Wang, X., Zhong, J., Wu, L., Li, A., Cao, M., Wu, Y., Shi, H., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.901495 · Cited by 120
Goedegebuure, P. S., Mitchem, J. B., Porembka, M. R., Tan, M. C. B., Belt, B. A., Wang‐Gillam, A., Gillanders, W. E., Hawkins, W. G., & Linehan, D. C. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796191024 · Cited by 118
Myeloid regulatory cells in tumor spreading and metastasis
Keskinov, A. A., & Shurin, M. R. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.07.017 · Cited by 116
Wang, J., Yu, F., Jia, X., Iwanowycz, S., Wang, Y., Huang, S., Ai, W., & Fan, D. (2014) · International Journal of Cancer · doi:10.1002/ijc.29151 · Cited by 109
Highlights of 10 years of immunology in Nature Reviews Immunology
Medzhitov, R., Shevach, E. M., Trinchieri, G., Mellor, A. L., Munn, D. H., Gordon, S., Libby, P., Hansson, G. K., Shortman, K., Dong, C., et al. (2011) · Nature Reviews Immunology · doi:10.1038/nri3063 · Cited by 100
Self-citationProspects for chimeric antigen receptor-modified T cell therapy for solid tumors
Zhang, E., Gu, J., & Xu, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0759-3 · Cited by 99
The impact of hypoxia on immune state in cancer
Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 106
MDSCs in cancer: Conceiving new prognostic and therapeutic targets
Sanctis, F. D., Solito, S., Ugel, S., Molon, B., Bronte, V., & Marigo, I. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.001 · Cited by 111
Myeloid‐derived suppressor cells as effectors of immune suppression in cancer
Pyzer, A. R., Cole, L., Rosenblatt, J., & Avigan, D. E. (2016) · International Journal of Cancer · doi:10.1002/ijc.30232 · Cited by 98
Metadata
- Authors
- Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Gabrilovich, Dmitry I.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-09-27
- Volume
- 207
- Issue
- 11
- Pages
- 2439-2453
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2964584
- OpenAlex
- W2109424201
- Semantic Scholar
- 77cf3cf3976e026979d2b7acf9b04119740a45f1
- Cited by
- 1,173
- References
- 56
- Citations by year
- 2026: 69 · 2025: 73 · 2024: 69 · 2023: 92 · 2022: 80 · 2021: 109 · 2020: 93 · 2019: 62 · 2018: 83 · 2017: 62 · 2016: 69 · 2015: 51 · 2014: 70 · 2013: 76 · 2012: 61
- FWCI
- 25.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Moffitt Cancer Center
- National Institutes of Health
- National Cancer Institute (CA84488, R01CA084488, R01CA103921, R01CA136828, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- myeloid-derived suppressor cells, HIF-1α, tumor microenvironment, hypoxia, tumor-associated macrophages, T cell suppression, arginase-1, inducible nitric oxide synthase, NADPH oxidase, reactive oxygen species, MDSC differentiation, immunosuppression
- MeSH terms
- Aged, Animals, Antigens, Neoplasm, Arginase, Cell Differentiation, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Middle Aged, Neoplasms, Cell Hypoxia, CD8-Positive T-Lymphocytes, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.